U-Neuron Biomedical Inc (6973) Stock Statistics & Valuation Metrics
Total Valuation
U-Neuron Biomedical Inc has a market cap or net worth of TWD 2.16B. The enterprise value is ―.
- Market Cap
- TWD 2.16B
- Enterprise Value
- ―
Share Statistics
U-Neuron Biomedical Inc has 40,803,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 40,803,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
U-Neuron Biomedical Inc’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -8.96%.
- Return on Equity (ROE)
- -0.08
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- -8.96%
- Return on Capital Employed (ROCE)
- -0.09
- Revenue Per Employee
- 2.76M
- Profits Per Employee
- -1.84M
- Employee Count
- 30
- Asset Turnover
- 0.11
- Inventory Turnover
- 2.47
Valuation Ratios
The current PE Ratio of U-Neuron Biomedical Inc is -36.41. U-Neuron Biomedical Inc’s PEG ratio is -0.36.
- PE Ratio
- -36.41
- PS Ratio
- 25.41
- PB Ratio
- 3.25
- Price to FCF
- -41.67
- Price to Operating Cash Flow
- -54.95
- PEG Ratio
- -0.36
Income Statement
In the last 12 months, U-Neuron Biomedical Inc had revenue of 82.66M and earned -55.29M in profits. Earnings per share was -1.42.
- Revenue
- 82.66M
- Gross Profit
- 55.39M
- Operating Income
- -65.18M
- Pretax Income
- -55.29M
- Net Income
- -55.29M
- EBITDA
- -50.66M
- Earnings Per Share (EPS)
- -1.42
Cash Flow
In the last 12 months, operating cash flow was -40.07M and capital expenditures -20.07M, giving a free cash flow of -60.14M billion.
- Operating Cash Flow
- -40.07M
- Free Cash Flow
- -60.14M
- Free Cash Flow per Share
- -1.55
Dividends & Yields
U-Neuron Biomedical Inc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.40%
- Earnings Yield
- -2.75%
Stock Price Statistics
- Beta
- 0.28
- 52-Week Price Change
- 21.05%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 38.64
- Average Volume (3m)
- 177.79K
Financial Position
U-Neuron Biomedical Inc as a current ratio of 16.48, with Debt / Equity ratio of 2.22%
- Current Ratio
- 16.48
- Quick Ratio
- 16.20
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 7.68
- Interest Coverage Ratio
- -103.63
Taxes
In the past 12 months, U-Neuron Biomedical Inc has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
U-Neuron Biomedical Inc EV to EBITDA ratio is -43.13, with an EV/FCF ratio of -34.93.
- EV to Sales
- 21.30
- EV to EBITDA
- -43.13
- EV to Free Cash Flow
- -34.93
- EV to Operating Cash Flow
- -52.41
Balance Sheet
U-Neuron Biomedical Inc has TWD 598.11M in cash and marketable securities with TWD 50.01M in debt, giving a net cash position of TWD 548.10M billion.
- Cash & Marketable Securities
- TWD 598.11M
- Total Debt
- TWD 50.01M
- Net Cash
- TWD 548.10M
- Net Cash Per Share
- TWD 13.43
- Tangible Book Value Per Share
- TWD 17.45
Margins
Gross margin is 65.61%, with operating margin of -70.91%, and net profit margin of -61.36%.
- Gross Margin
- 65.61%
- Operating Margin
- -70.91%
- Pretax Margin
- -61.36%
- Net Profit Margin
- -61.36%
- EBITDA Margin
- -49.38%
- EBIT Margin
- -70.91%
Analyst Forecast
The average price target for U-Neuron Biomedical Inc is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 50.58%
- EPS Growth Forecast
- -22.49%
